Cellphire
Rockville, US · Delaware corporation · 2 known investors
Cellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.
Founders & leadership

Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$5M disclosed across 2 rounds · 2023–2025
▶$3MraisedDec 2025 · 19 investors · BiotechnologyRule 506(b)
- Pamela ConleyDirector
- Rafael JordaDirector
- Thomas DubinDirector
- Michael GaffneyExecutive Officer, Director
- Derek WoodsDirector
- Randall StanickyDirector
- James PeakeDirector
- Offering amount
- $3M
- Amount sold
- $3M
- Minimum investment
- $17.7K
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedOct 2023 · 1 investors · BiotechnologyRule 506(b)
- David HirshDirector
- Cristiane WolfeExecutive Officer
- Michael GaffneyExecutive Officer, Director
- Rafael JordaDirector
- Derek WoodsDirector
- James PeakeDirector
- Thomas DubinDirector
- Angela HowertonExecutive Officer
- Pamela ConleyDirector
- Rob WoodsExecutive Officer
- Offering amount
- $8M
- Amount sold
- $2M
- Minimum investment
- $100K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapCompanies competing with Cellphire for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseSpecial Operations Command | Phase I | 2017 | $149.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Cellphire do?
- Cellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.
- Who are Cellphire's investors?
- Cellphire's investors include Circadian Ventures, Manta Ray Ventures.
- How much funding has Cellphire raised?
- Cellphire has disclosed $5M raised across 2 rounds.
- Where is Cellphire headquartered?
- Cellphire is headquartered in Rockville, US.